News | Nanologica

NOTICE OF THE ANNUAL GENERAL MEETING 2023 NANOLOGICA AB (PUBL)

5 April, 2023

English translation for information purposes only. If there are differences between the English translation and the Swedish original, the Swedish text will take precedence. The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby summoned to the Annual General Meeting on Thursday, May 4, 2023, at 12.00 CET, at Redeye's premises at Mäster Samuelsgatan 42, Stockholm. Right to attend the meeting Shareholders who wish to participate in the Annual General Meeting must: •

KALLELSE TILL ÅRSSTÄMMA I NANOLOGICA AB (PUBL)

5 April, 2023

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till årsstämma torsdagen den 4 maj 2023, klockan 12.00, i Redeyes lokaler på Mäster Samuelsgatan 42, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i årsstämman ska: • dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken tisdagen den 25 april 2023, • dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast fredagen den

Nanologica’s Annual Report 2022 Published

24 March, 2023

Nanologica AB’s annual report for 2022 is now published on the company’s website. The annual report in Swedish, and an English translation, is available on www.nanologica.com as a pdf. The annual report in Swedish is also available in the European Single Electronic Format (ESEF). Swedish: https://nanologica.com/category/finansiella-rapporter/ English translation: https://nanologica.com/category/financial-reports/ For further information, please contact: Johanna Johansson, Director IR, Communications and Marketing Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com This information is information that

Nanologicas årsredovisning 2022 publicerad

24 March, 2023

Nanologica AB:s årsredovisning för 2022 finns nu publicerad på bolagets hemsida. Årsredovisningen på svenska liksom en engelsk översättning finns tillgänglig på www.nanologica.com i pdf-format. Årsredovisningen på svenska finns även tillgänglig i European Single Electronic Format (ESEF). Svenska: https://nanologica.com/category/finansiella-rapporter/ Engelsk översättning: https://nanologica.com/category/financial-reports/ För ytterligare information, vänligen kontakta: Johanna Johansson, Director IR, Communications and MarketingTel: +46 72 211 21 90 eller e-post: ir@nanologica.com Denna information är sådan information som Nanologica AB är skyldig att offentliggöra enligt lagen (2005:528)

Nanologica’s Year-End Report 2022

10 February, 2023

FINANCIAL SUMMARY Net sales for the fourth quarter amounted to TSEK 674 (676) and for the full year to TSEK 1,555 (12,914) The operating loss for the quarter amounted to TSEK -13,251 (-14,108) and for the full year to TSEK -50,850 (-40,689) Loss after tax for the quarter amounted to TSEK -14,855 (-15,222) and for the full year to TSEK -55,231 (-44,829) Earnings per share before and after dilution were SEK -0.42 (-0.54) for the

Nanologicas bokslutskommuniké 2022

10 February, 2023

FINANSIELL SAMMANFATTNING · Nettoomsättningen för fjärde kvartalet uppgick till 674 TSEK (676) och för helåret till 1 555 TSEK (12 914) · Rörelseresultatet för kvartalet uppgick till -13 251 TSEK (-14 108) och för helåret till -50 850 TSEK (-40 689) · Resultatet efter skatt för kvartalet uppgick till -14 855 TSEK (-15 222) och för helåret till -55 231 TSEK (-44 829) · Resultat per aktie före och efter utspädning var -0,42 SEK (-0,54)

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.